Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus LIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus LIDEX.
DERMA-SMOOTHE/FS vs LIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokines and immune cell migration.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life: 28-36 hours. Clinical context: Steady-state achieved in ~5-7 days; once-daily dosing maintains therapeutic levels without accumulation in patients with normal renal function.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Renal (primarily as metabolites) ~ 95%; biliary/fecal ~5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid